Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia

Jorge Cortes, Andreas Hochhaus, Timothy Hughes, Hagop Kantarjian

Research output: Contribution to journalReview article

Abstract

Chronic myeloid leukemia (CML) has been a model disease in the development of targeted therapies. After nearly 40 years of the recognition of the chromosomal abnormality that defines CML, specific therapy was developed, initially with imatinib mesylate, which has transformed our treatment algorithms and has changed the natural history of the disease. Today, most patients have the expectation of a favorable outcome when treated with standard-dose imatinib. However, a significant proportion of patients do not achieve the optimal desirable outcome. Effective salvage therapy followed the recognition of some of the most common mechanisms of resistance. More recently, the focus has turned to new areas of research and medical need, such as improving the front-line therapy to minimize the risk of resistance, to fight the most resistant mutant forms of BCR-ABL, and to eliminate minimal residual disease with the goal of achieving total elimination of the disease and treatment discontinuation. In this review, we analyze the current status of therapy of CML, and we discuss some of the most relevant clinical questions that we face today.

Original languageEnglish (US)
Pages (from-to)524-531
Number of pages8
JournalJournal of Clinical Oncology
Volume29
Issue number5
DOIs
StatePublished - Feb 10 2011
Externally publishedYes

Fingerprint

Salvage Therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Therapeutics
Disease Eradication
Residual Neoplasm
Chromosome Aberrations
Biomedical Research

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. / Cortes, Jorge; Hochhaus, Andreas; Hughes, Timothy; Kantarjian, Hagop.

In: Journal of Clinical Oncology, Vol. 29, No. 5, 10.02.2011, p. 524-531.

Research output: Contribution to journalReview article

Cortes, Jorge ; Hochhaus, Andreas ; Hughes, Timothy ; Kantarjian, Hagop. / Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 5. pp. 524-531.
@article{0b3484fe307749ee9b5aed5aae505914,
title = "Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia",
abstract = "Chronic myeloid leukemia (CML) has been a model disease in the development of targeted therapies. After nearly 40 years of the recognition of the chromosomal abnormality that defines CML, specific therapy was developed, initially with imatinib mesylate, which has transformed our treatment algorithms and has changed the natural history of the disease. Today, most patients have the expectation of a favorable outcome when treated with standard-dose imatinib. However, a significant proportion of patients do not achieve the optimal desirable outcome. Effective salvage therapy followed the recognition of some of the most common mechanisms of resistance. More recently, the focus has turned to new areas of research and medical need, such as improving the front-line therapy to minimize the risk of resistance, to fight the most resistant mutant forms of BCR-ABL, and to eliminate minimal residual disease with the goal of achieving total elimination of the disease and treatment discontinuation. In this review, we analyze the current status of therapy of CML, and we discuss some of the most relevant clinical questions that we face today.",
author = "Jorge Cortes and Andreas Hochhaus and Timothy Hughes and Hagop Kantarjian",
year = "2011",
month = "2",
day = "10",
doi = "10.1200/JCO.2010.31.3619",
language = "English (US)",
volume = "29",
pages = "524--531",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia

AU - Cortes, Jorge

AU - Hochhaus, Andreas

AU - Hughes, Timothy

AU - Kantarjian, Hagop

PY - 2011/2/10

Y1 - 2011/2/10

N2 - Chronic myeloid leukemia (CML) has been a model disease in the development of targeted therapies. After nearly 40 years of the recognition of the chromosomal abnormality that defines CML, specific therapy was developed, initially with imatinib mesylate, which has transformed our treatment algorithms and has changed the natural history of the disease. Today, most patients have the expectation of a favorable outcome when treated with standard-dose imatinib. However, a significant proportion of patients do not achieve the optimal desirable outcome. Effective salvage therapy followed the recognition of some of the most common mechanisms of resistance. More recently, the focus has turned to new areas of research and medical need, such as improving the front-line therapy to minimize the risk of resistance, to fight the most resistant mutant forms of BCR-ABL, and to eliminate minimal residual disease with the goal of achieving total elimination of the disease and treatment discontinuation. In this review, we analyze the current status of therapy of CML, and we discuss some of the most relevant clinical questions that we face today.

AB - Chronic myeloid leukemia (CML) has been a model disease in the development of targeted therapies. After nearly 40 years of the recognition of the chromosomal abnormality that defines CML, specific therapy was developed, initially with imatinib mesylate, which has transformed our treatment algorithms and has changed the natural history of the disease. Today, most patients have the expectation of a favorable outcome when treated with standard-dose imatinib. However, a significant proportion of patients do not achieve the optimal desirable outcome. Effective salvage therapy followed the recognition of some of the most common mechanisms of resistance. More recently, the focus has turned to new areas of research and medical need, such as improving the front-line therapy to minimize the risk of resistance, to fight the most resistant mutant forms of BCR-ABL, and to eliminate minimal residual disease with the goal of achieving total elimination of the disease and treatment discontinuation. In this review, we analyze the current status of therapy of CML, and we discuss some of the most relevant clinical questions that we face today.

UR - http://www.scopus.com/inward/record.url?scp=79952081141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952081141&partnerID=8YFLogxK

U2 - 10.1200/JCO.2010.31.3619

DO - 10.1200/JCO.2010.31.3619

M3 - Review article

C2 - 21220597

AN - SCOPUS:79952081141

VL - 29

SP - 524

EP - 531

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -